We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”

Learn more about it by watching THIS NOW.

Cindy Tahl Biography and Net Worth

General Counsel of Fate Therapeutics

Cindy Tahl is General Counsel at Fate Therapeutics and is serving as a key advisor in day to day operations, providing legal advice and counsel for all functions of the business and overseeing company compliance. Ms. Tahl also directs the development and expansion of the Company’s IP portfolio. Prior to joining Fate, Ms. Tahl was a technology transactions attorney at Wilson Sonsini Goodrich & Rosati, P.C., and practiced intellectual property law in the New York office of Kenyon & Kenyon, LLP. Ms. Tahl has worked extensively with biotechnology companies at all stages of growth, representing clients in numerous corporate transactions and executing patent strategy to advance corporate goals. Ms. Tahl received a J.D. from Boston College Law School and a B.S. in biology from the University of California, San Diego. She is admitted to the state bars of California and New York, and is registered to practice as a patent attorney before the U.S. Patent and Trademark Office.

What is Cindy Tahl's net worth?: The estimated net worth of Cindy Tahl is at least $267,638.68 as of January 9th, 2024. Ms. Tahl owns 142,361 shares of Fate Therapeutics stock worth more than $267,639 as of December 18th. This net worth estimate does not reflect any other assets that Ms. Tahl may own. Additionally, Ms. Tahl receives an annual salary of $612,500.00 as General Counsel at Fate Therapeutics. Learn More about Cindy Tahl's net worth.
How old is Cindy Tahl?: Ms. Tahl is currently 51 years old. There are 3 older executives and no younger executives at Fate Therapeutics. The oldest executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who is 54 years old. Learn More on Cindy Tahl's age.
What is Cindy Tahl's salary?: As the General Counsel of Fate Therapeutics, Inc., Ms. Tahl earns $612,500.00 per year. There are 2 executives that earn more than Ms. Tahl. The highest earning executive at Fate Therapeutics is Mr. J. Scott Wolchko, Founder, CEO, President & Director, who commands a salary of $920,400.00 per year. Learn More on Cindy Tahl's salary.
How do I contact Cindy Tahl?: The corporate mailing address for Ms. Tahl and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected]. Learn More on Cindy Tahl's contact information.
Has Cindy Tahl been buying or selling shares of Fate Therapeutics?: Cindy Tahl has not been actively trading shares of Fate Therapeutics during the past quarter. Most recently, Cindy Tahl sold 10,874 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a transaction totalling $47,519.38. Following the completion of the sale, the general counsel now directly owns 142,361 shares of the company's stock, valued at $622,117.57. Learn More on Cindy Tahl's trading history.
Who are Fate Therapeutics' active insiders?: Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.
Are insiders buying or selling shares of Fate Therapeutics?: In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company. Learn More about insider trades at Fate Therapeutics.
Information on this page was last updated on 8/6/2024.

Cindy Tahl Insider Trading History at Fate Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2024	Sell	10,874	$4.37	$47,519.38	142,361
1/10/2023	Sell	11,553	$5.24	$60,537.72	177,598
4/1/2022	Sell	25,000	$38.85	$971,250.00	189,151
1/10/2022	Sell	7,738	$46.43	$359,275.34
10/1/2021	Sell	50,000	$58.83	$2,941,500.00
4/1/2021	Sell	30,000	$83.81	$2,514,300.00	136,197
1/19/2021	Sell	35,000	$114.76	$4,016,600.00	125,035
1/11/2021	Sell	9,483	$114.94	$1,089,976.02	96,763
1/8/2021	Sell	6,229	$117.10	$729,415.90	96,763
10/16/2020	Sell	29,199	$50.25	$1,467,249.75	128,717
10/15/2019	Sell	10,200	$14.24	$145,248.00
3/1/2019	Sell	25,000	$16.15	$403,750.00	115,418
2/25/2019	Sell	25,000	$16.07	$401,750.00	115,418
1/7/2019	Sell	25,000	$16.00	$400,000.00	47,426
10/16/2017	Sell	8,091	$3.85	$31,150.35

Cindy Tahl Buying and Selling Activity at Fate Therapeutics

Fate Therapeutics Company Overview

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Today's Range

Now: $1.88

$1.85

$2.02

50 Day Range

MA: $2.63

$1.83

$3.23

2 Week Range

Now: $1.88

$1.82

$8.83

Volume

2,811,176 shs

Average Volume

2,407,703 shs

Market Capitalization

$214.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.95

The #1 Crypto for AI

From Weiss Ratings | Ad

Learn more about it by watching THIS NOW.

Cindy Tahl Biography and Net Worth

What is Cindy Tahl's net worth?

How old is Cindy Tahl?

What is Cindy Tahl's salary?

How do I contact Cindy Tahl?

Has Cindy Tahl been buying or selling shares of Fate Therapeutics?

Who are Fate Therapeutics' active insiders?

Are insiders buying or selling shares of Fate Therapeutics?